Establishment and characteristics of GWH04, a new primary human glioblastoma cell line

Cheng,Fangling; Wan,Xueyan; Wang,Baofeng; Li,Youwei; Peng,Peng; Xu,Sanpeng; Han,Chao; Mao,Feng; Guo,Dongsheng

doi:10.3892/ijo.2022.5429

Establishment and characteristics of GWH04, a new primary human glioblastoma cell line

Authors:
- Fangling Cheng
- Xueyan Wan
- Baofeng Wang
- Youwei Li
- Peng Peng
- Sanpeng Xu
- Chao Han
- Feng Mao
- Dongsheng Guo
View Affiliations

Affiliations: Hubei Key Laboratory of Hepato‑Pancreato‑Biliary Diseases, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China, Department of Neurosurgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China, Institute of Pathology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R. China, Department of Neurosurgery, The First Hospital of Laohekou, Xiangyang, Hubei 441800, P.R. China
Published online on: September 26, 2022 https://doi.org/10.3892/ijo.2022.5429
Article Number: 139
Copyright: © Cheng et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Glioblastoma multiforme (GBM) is a common and fatal disease of the central nervous system. GBM cell lines are fundamental tools used in GBM research. The establishment of novel continuous GBM cell lines with clear genetic backgrounds could facilitate the exploration of molecular mechanisms and the screening and evaluation of antitumor drugs in GBM studies. In the present study, a novel primary glioblastoma cell line was established, named GWH04, from a patient with GBM, and its STR genotype and various tumor parameters were examined. The STR information of GWH04 was identical to that of the original primary tumor tissue. Compared with existing cell lines, GWH04 had a similar in vitro proliferation rate as the U87 cell line, but a faster rate than the GL15 cell line, and substantial soft agar clone‑formation capacity and subcutaneous and intracranial tumorigenic capacity. For drug sensitivity test, half maximal inhibitory concentration assays for multiple drugs were performed in these three cell lines, and GWH04 cells were found to be resistant to temozolomide. Aneuploid karyotype with a median of 84 chromosomes was possessed by GWH04, as well as chromosomal structural abnormalities, such as broken chromosomes, double centromere chromosomes, homogeneous staining regions, and double microbodies. Gene sequencing further revealed the mutational status of genes TP53, PTEN, PDGFRA, ERBB2, BRCA1, NF1, and MLH1 and the promoter region of telomerase reverse transcriptase (C228T) in this cell line. Altogether, these results indicated that GWH04 will be a useful tool for human GBM studies both in vitro and in vivo.

View Figures

View References

1	Wen PY and Reardon DA: Neuro-oncology in 2015: rogress in glioma diagnosis, classification and treatment. Nat Rev Neurol. 12:69–70. 2016. View Article : Google Scholar : PubMed/NCBI
2	Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, et al: Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell. 17:510–522. 2010. View Article : Google Scholar : PubMed/NCBI
3	Allen M, Bjerke M, Edlund H, Nelander S and Westermark B: Origin of the U87MG glioma cell line: Good news and bad news. Sci Transl Med. 8:354re32016. View Article : Google Scholar : PubMed/NCBI
4	Bigner DD, Bigner SH, Pontén J, Westermark B, Mahaley MS, Ruoslahti E, Herschman H, Eng LF and Wikstrand CJ: Heterogeneity of genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas. J Neuropathol Exp Neurol. 40:201–229. 1981. View Article : Google Scholar : PubMed/NCBI
5	Diserens AC, de Tribolet N, Martin-Achard A, Gaide AC, Schnegg JF and Carrel S: Characterization of an established human malignant glioma cell line: LN-18. Acta Neuropathol. 53:21–28. 1981. View Article : Google Scholar : PubMed/NCBI
6	Van Meir E, Sawamura Y, Diserens AC, Hamou MF and de Tribolet N: Human glioblastoma cells release interleukin 6 in vivo and in vitro. Cancer Res. 50:6683–6688. 1990.PubMed/NCBI
7	Ishii N, Maier D, Merlo A, Tada M, Sawamura Y, Diserens AC and Van Meir EG: Frequent co-alterations of TP53, p16/CDKN2A, p14ARF, PTEN tumor suppressor genes in human glioma cell lines. Brain Pathol. 9:469–479. 1999. View Article : Google Scholar : PubMed/NCBI
8	Van Meir EG, Kikuchi T, Tada M, Li H, Diserens AC, Wojcik BE, Huang HJ, Friedmann T, de Tribolet N and Cavenee WK: Analysis of the p53 gene and its expression in human glioblastoma cells. Cancer Res. 54:649–652. 1994.PubMed/NCBI
9	Bocchini V, Casalone R, Collini P, Rebel G and Lo Curto F: Changes in glial fibrillary acidic protein and karyotype during culturing of two cell lines established from human glioblastoma multiforme. Cell Tissue Res. 265:73–81. 1991. View Article : Google Scholar : PubMed/NCBI
10	Bian X, Yang Z, Feng H, Sun H and Liu Y: A combination of species identification and STR profiling identifies cross-contaminated cells from 482 human tumor cell lines. Sci Rep. 7:97742017. View Article : Google Scholar : PubMed/NCBI
11	Louis DN, Perry A, Reifenberger G, von Deimling A, Figarella-Branger D, Cavenee WK, Ohgaki H, Wiestler OD, Kleihues P and Ellison DW: The 2016 World Health Organization classification of tumors of the central nervous system: A summary. Acta Neuropathol. 131:803–820. 2016. View Article : Google Scholar : PubMed/NCBI
12	Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al: Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-Year analysis of the EORTC-NCIC trial. Lancet Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
13	Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel M, Hau P, Kortmann RD, Krex D, Grauer O, et al: Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblas-0toma with methylated MGMT promoter (CeTeG/NOA-09): A randomised, open-label, phase 3 trial. Lancet. 393:678–688. 2019. View Article : Google Scholar : PubMed/NCBI
14	Killock D: Lomustine-temozolomide combination efficacious in newly diagnosed glioblastoma. Nat Rev Clin Oncol. 16:2732019.
15	Wick W, Gorlia T, Bendszus M, Taphoorn M, Sahm F, Harting I, Brandes AA, Taal W, Domont J, Idbaih A, et al: Lomustine and bevacizumab in progressive glioblastoma. New Engl J Med. 377:1954–1963. 2017. View Article : Google Scholar : PubMed/NCBI
16	Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, et al: Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 27:4733–4740. 2009. View Article : Google Scholar : PubMed/NCBI
17	Jeremic B, Grujicic D, Jevremovic S, Stanisavljevic B, Milojevic L, Djuric L and Mijatovic L: Carboplatin and etoposide chemotherapy regimen for recurrent malignant glioma: A phase II study. J Clin Oncol. 10:1074–1077. 1992. View Article : Google Scholar : PubMed/NCBI
18	Buckner JC, Ballman KV, Michalak JC, Burton GV, Cascino TL, Schomberg PJ, Hawkins RB, Scheithauer BW, Sandler HM, Marks RS, et al: Phase III trial of carmustine and cisplatin compared with carmustine alone and standard radiation therapy or accelerated radiation therapy in patients with glioblastoma multiforme: North central cancer treatment group 93-72-52 and southwest oncology group 9503 trials. J Clin Oncol. 24:3871–3879. 2006. View Article : Google Scholar : PubMed/NCBI
19	Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, Davidson CJ, Akhavanfard S, Cahill DP, Aldape KD, Betensky RA, et al: Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. Cancer Cell. 20:810–817. 2011. View Article : Google Scholar : PubMed/NCBI
20	Yi GZ, Huang G, Guo M, Zhang X, Wang H, Deng S, Li Y, Xiang W, Chen Z, Pan J, et al: Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2. Brain. 142:2352–2366. 2019. View Article : Google Scholar : PubMed/NCBI
21	McLendon R, Friedman A, Bigner D, Van Meir EG, Brat DJ, Mastrogianakis GM, Olson JJ, Mikkelsen T, Lehman N, Aldape K, et al: Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature. 455:1061–1068. 2008. View Article : Google Scholar
22	Yao PS, Kang DZ, Wang XF, Lin RY and Ye ZC: Cell-density-dependent manifestation of partial characteristics for neuronal precursors in a newly established human gliosarcoma cell line. In Vitro Cell Dev Biol Anim. 51:345–352. 2015. View Article : Google Scholar
23	Notarangelo A, Trombetta D, D'Angelo V, Parrella P, Palumbo O, Storlazzi CT, Impera L, Muscarella LA, La Torre A, Affuso A, et al: Establishment and genetic characterization of ANGM-CSS, a novel, immortal cell line derived from a human glioblastoma multiforme. Int J Oncol. 44:717–724. 2014. View Article : Google Scholar
24	Li Y, Sun T, Chen Z, Shao Y, Huang Y and Zhou Y: Characterization of a new human astrocytoma cell line SHG140: Cell proliferation, cell phenotype, karyotype, STR markers and tumorigenicity analysis. J Cancer. 12:371–378. 2021. View Article : Google Scholar : PubMed/NCBI
25	Li Y, Wang H, Sun T, Chen J, Guo L, Shen H, Du Z and Zhou Y: Biological characteristics of a new human glioma cell line transformed into A2B5(+) stem cells. Mol Cancer. 14:752015. View Article : Google Scholar : PubMed/NCBI
26	Man J, Yu X, Huang H, Zhou W, Xiang C, Huang H, Miele L, Liu Z, Bebek G, Bao S and Yu JS: Hypoxic induction of vasorin regulates notch1 turnover to maintain glioma stem-like cells. Cell Stem Cell. 22:104–118.e6. 2018. View Article : Google Scholar :
27	Aubrey BJ, Strasser A and Kelly GL: Tumor-suppressor functions of the TP53 pathway. Cold Spring Harb Perspect Med. 6:a0260622016. View Article : Google Scholar : PubMed/NCBI
28	Bouaoun L, Sonkin D, Ardin M, Hollstein M, Byrnes G, Zavadil J and Olivier M: TP53 variations in human cancers: New lessons from the IARC TP53 database and genomics data. Hum Mutat. 37:865–876. 2016. View Article : Google Scholar : PubMed/NCBI
29	Cesare AJ and Reddel RR: Alternative lengthening of telomeres: Models, mechanisms and implications. Nat Rev Genet. 11:319–330. 2010. View Article : Google Scholar : PubMed/NCBI
30	Labussière M, Di Stefano AL, Gleize V, Boisselier B, Giry M, Mangesius S, Bruno A, Paterra R, Marie Y, Rahimian A, et al: TERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations. Br J Cancer. 111:2024–2032. 2014. View Article : Google Scholar : PubMed/NCBI
31	Dewhurst SM, McGranahan N, Burrell RA, Rowan AJ, Grönroos E, Endesfelder D, Joshi T, Mouradov D, Gibbs P, Ward RL, et al: Tolerance of whole-genome doubling propagates chromosomal instability and accelerates cancer genome evolution. Cancer Discov. 4:175–185. 2014. View Article : Google Scholar : PubMed/NCBI
32	Kim H, Nguyen NP, Turner K, Wu S, Gujar AD, Luebeck J, Liu J, Deshpande V, Rajkumar U, Namburi S, et al: Extrachromosomal DNA is associated with oncogene amplification and poor outcome across multiple cancers. Nat Genet. 52:891–897. 2020. View Article : Google Scholar : PubMed/NCBI
33	Koche RP, Rodriguez-Fos E, Helmsauer K, Burkert M, MacArthur IC, Maag J, Chamorro R, Munoz-Perez N, Puiggròs M, Dorado Garcia H, et al: Extrachromosomal circular DNA drives oncogenic genome remodeling in neuroblastoma. Nat Genet. 52:29–34. 2020. View Article : Google Scholar :
34	Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, Eskin A, Hwang K, Wang J, Masui K, et al: Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science. 343:72–76. 2014. View Article : Google Scholar :
35	Turner KM, Deshpande V, Beyter D, Koga T, Rusert J, Lee C, Li B, Arden K, Ren B, Nathanson DA, et al: Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity. Nature. 543:122–125. 2017. View Article : Google Scholar : PubMed/NCBI
36	Percie du Sert N, Ahluwalia A, Alam S, Avey MT, Baker M, Browne WJ, Clark A, Cuthill IC, Dirnagl U, Emerson M, et al: Reporting animal research: Explanation and elaboration for the ARRIVE guidelines 2.0. PLoS Biol. 18:e30004112020. View Article : Google Scholar : PubMed/NCBI